ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0722

Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies

Rashmi Dhital1, Rebecca Baer2, Monica Guma2, Kenneth Kalunian2, Accelerating Medicines Partnership Program RA SLE Network3 and Christina Chambers2, 1UC San Diego, San Diego, CA, 2University of California San Diego, La Jolla, CA, 3Cedars-Sinai Medical Center, Los Angeles, CA

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, Cardiovascular, Epidemiology, Heart disease, pregnancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: Plenary I

Session Type: Plenary Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Cardiovascular diseases (CVDs) complicate 1-4% of pregnancies. Autoimmune rheumatic diseases (ARDs) are associated with a 1.5 to 3-fold higher CVD risk. Similarly, antiphospholipid syndrome (APS) is associated with increased risks of thromboembolism, pregnancy loss, and CVDs. However, research on the impact of ARDs and APS on maternal cardiovascular health is limited. In this study, we aim to compare the rates of acute CVEs in pregnant women with ARDs and primary APS as compared to a general population of pregnant women with neither condition, using a large population-based birth cohort in California.

Methods: We retrospectively analyzed pregnant individuals who delivered singleton liveborn infants in California between 2005-2020. Birth certificates were linked by the California Study of Outcomes in Mothers and Infants (SOMI) to maternal hospital discharge, emergency department and ambulatory surgery records. We identified ARDs, APS, and acute CVEs during pregnancy and up to 6 weeks postpartum using ICD codes. We used logistic regression to calculate adjusted relative risks (RRs) and 95% confidence intervals (CI) of association between acute CVEs and ARDs and APS, for each specific category of ARDs, and for CVEs by timing in relation to delivery. We performed mediation analysis to investigate if pregnancy complications such as gestational diabetes mellitus (GDM) and pre-eclampsia mediated the association between ARDs and CVEs.

Results: CVEs occurred in 2.0% of 19,340 pregnant women with ARDs, 6.9% of 7,758 women with primary APS, and 0.4% of 7,004,334 women with neither. The risks of acute CVEs were significantly higher for pregnant women with ARDs (aRR 4.1, 95% CI 3.7, 4.5) and primary APS (aRR 14.7, 95% CI 13.5,16.0) than for the comparison group. Systemic lupus erythematosus (SLE) was associated with a 6-fold increased risk for CVE, which was further elevated with concomitant APS or nephritis (aRRs 18.1 and 12.7, respectively). (Figure 1). Only 12% of the excess association of acute CVEs with an ARD was mediated by preeclampsia and < 1% by GDM. About 25-30% of the CVEs occurred postpartum as documented in readmission records. This represented a 6-fold greater risk than in the comparison group (Table 2).

Conclusion: Pregnant women with ARDs and primary APS have significantly higher risks for acute CVEs compared to pregnant women without these conditions, with the highest risks among those with SLE with concomitant APS, followed by primary APS and SLE with nephritis. Furthermore, about 25-30% of CVEs occurred during the postpartum period, highlighting the importance of close monitoring of cardiovascular risks and events in women with ARDs or APS both during pregnancy and postpartum.

Supporting image 1

Figure 1. Comparison of risks of acute cardiovascular events during pregnancy or within 6 weeks post-partum for autoimmune rheumatic diseases (ARDs) and primary antiphospholipid syndrome (APS) as compared to the comparison group with neither condition, 2005 – 2020
#Adjusted relative risks (aRRs) adjusted for baseline covariates that occurred before pregnancy (maternal age at delivery, race/ethnicity, payer for delivery, maternal education, maternal pre-pregnancy body mass index, preexisting hypertension, preexisting diabetes, hyperlipidemia, smoking, alcohol use, drug use, and depression).
* APS: antiphospholipid syndrome, ARD: autoimmune rheumatic disease, RA: rheumatoid arthritis, SLE: systemic lupus erythematosus, LN: lupus nephritis, SS: Sjogren’s syndrome, * Other ARDs (Systemic sclerosis, myositis, vasculitis)

Supporting image 2

Table 2. Rates of acute cardiovascular events by timing in relation to delivery for autoimmune rheumatic diseases (ARDs) and primary antiphospholipid syndrome (APS) as compared to the comparison group with neither condition, 2005 – 2020
*ARD: autoimmune rheumatic disease, APS: antiphospholipid syndrome, CVE: cardiovascular event, ED: emergency department


Disclosures: R. Dhital: None; R. Baer: None; M. Guma: None; K. Kalunian: AbbVie/Abbott, 2, Amgen, 5, AstraZeneca, 2, Aurinia, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, EquilliumBio, 2, Genentech, 2, Gilead, 2, Janssen, 2, KezarBio, 1, Merck/MSD, 2, Novartis, 2, Pfizer, 2, Remegene, 2, Roche, 2, UCB, 5; A. RA SLE Network: None; C. Chambers: Amgen, 5, AstraZeneca, 5, Bristol-Myers Squibb(BMS), 5, Genzyme Sanofi-Aventis, 5, Gerber Foundation, 5, Gilead, 5, GlaxoSmithKline, 5, Hoffman La-Roche-Genentech, 5, Janssen Pharmaceuticals, 5, Leo Pharma, 5, Novartis, 5, Pfizer, Inc., 5, Regeneron, 5, Sanofi, 5, Sun Pharma Global FZE, 5, Takeda Pharmaceutical Company Limited, 5, UCB Pharma, USA, 5.

To cite this abstract in AMA style:

Dhital R, Baer R, Guma M, Kalunian K, RA SLE Network A, Chambers C. Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/acute-cardiovascular-events-in-autoimmune-rheumatic-disease-pregnancies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/acute-cardiovascular-events-in-autoimmune-rheumatic-disease-pregnancies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology